The Clearity Foundation
Newsletters
General Newsletters
2015
September 2015
2014
May 2014
2013
November 2013
June 2013
March 2013
2012
December 2012
November 2012
October 2012
July 2012
2011
December 2011
September 2011
Summer 2011
March 2011
2010
December 2010
Patient Newsletters
2015
Molecular Profiling as a Necessity for Uncommon Ovarian Cancers
2014
The Cutting Edge Science of Clinical Trials: Part 7 (2014 Clinical Advances; Avastin and PARPi Response Signatures)
Sept 2014: The Cutting Edge Science of Clinical Trials Part 6 (Novel trial design to match drugs)
March 2014: The Cutting Edge Science of Clinical Trials Part 5 (Eligibility: Viable Tissue; Immunotherapy)
2013
November 2013: The Cutting Edge Science of Clinical Trials Part 4 (Eligibility; How to Use Your Clearity Profile)
July 2013: The Cutting Edge Science of Clinical Trials Part 3 (Maintenance; PARP; BRCA)
May 2013: The Cutting Edge Science of Clinical Trials Part 2 (Phase 1; DMUC5754A-CA125-ADC)
February 2013: The Cutting Edge Science of Clinical Trials Part 1 (Basics; Why Now?)
2012
October 2012: How the Cancer Genome Atlas Is Changing Ovarian Cancer Treatment
2011
September 2011: Easter Island to Ovarian Cancer Trials
Summer 2011: Blazing the Trail for Biomarkers in Ovarian Cancer
March 2011: Exploring the Path Less Traveled
February 2011: Aware, Share, Care
2010
September 2010: Fighting Cancer by Disabling DNA
May 2010: Choking off a Tumor’s Blood Supply
February 2010: Considering Clinical Trials